New hope for painful mouth condition: baricitinib trial launches
NCT ID NCT06158113
First seen Jan 23, 2026 · Last updated May 23, 2026 · Updated 21 times
Summary
This study tests whether baricitinib, a drug that calms the immune system, can help people with moderate to severe oral lichen planus—a painful mouth condition. Ten adults who haven't improved with other treatments will take baricitinib daily for six months. Researchers will measure changes in mouth sores and quality of life, and watch for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL LICHEN PLANUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UNC Dermatology and Skin Cancer Center
Chapel Hill, North Carolina, 27516, United States
Conditions
Explore the condition pages connected to this study.